Patents-Review.com
ClassID:

110016 ⎘

C12N2710/24132 - CPC Classification

Classification description:

dsDNA viruses; Details; Poxviridae; Orthopoxvirus, e.g. vaccinia virus, variola Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Recent Application in this class:
#1
20260151445
2026-06-04

USE OF DR-18 AND ONCOLYTIC VACCINIA VIRUS IN PREPARATION OF ANTI-TUMOR DRUG

 #2
20260137740
2026-05-21

IRF MODULATOR-EXPRESSING ONCOLYTIC VIRUSES FOR TREATING CANCER

 #3
20260071233
2026-03-12

RECOMBINANT VIRUS EXPRESSING INTERLEUKIN-12

 #4
20260015405
2026-01-15

FUSION PROTEIN COMPRISING A SURFACTANT-PROTEIN-D AND A MEMBER OF THE TNFSF

 #5
20250302899
2025-10-02

COMPOSITIONS OF CD47/SIRP-ALPHA IMMUNE CHECKPOINT INHIBITORS AND USES THEREOF

 #6
20250297002
2025-09-25

BISPECIFIC T-CELL ENGAGER, RECOMBINANT ONCOLYTIC VIRUS THEREOF, AND USE THEREOF

 #7
20250177518
2025-06-05

RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS

 #8
20250090580
2025-03-20

METHODS AND COMPOSITIONS FOR USING ACTIVATED LYMPHOCYTES IN THE TREATMENT OF DISEASE

 #9
20250084384
2025-03-13

CHIMERIC POXVIRUS COMPOSITIONS AND USES THEREOF

 #10
20250064873
2025-02-27

TNFSF-L Fusion Proteins and Uses Thereof

 #11
20250041368
2025-02-06

Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling

 #12
20250009824
2025-01-09

Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling

 #13
20250002551
2025-01-02

INTERLEUKIN 7 AND INTERLEUKIN 21 FUSION PROTEINS

 #14
20240245804
2024-07-25

Expression of Bacterial Dinucleotide Cyclases

 #15
20240229069
2024-07-11

MODIFIED ORTHOPOXVIRUS VECTORS

 #16
20240132913
2024-04-25

MODIFIED ORTHOPOXVIRUS VECTORS

 #17
20240016865
2024-01-18

Oncolytic viruses targeting STAT3

 #18
20230355691
2023-11-09

NOVEL RECOMBINANT VACCINIA VIRUS AND USE THEREOF

 #19
20230346863
2023-11-02

Immuno-modulated replication-efficient Vaccinia virus strain

 #20
20230310526
2023-10-05

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

 #21
20230293608
2023-09-21

Oncolytic Vaccinia Virus

 #22
20230256041
2023-08-17

Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling

 #23
20230201283
2023-06-29

RECOMBINANT VACCINIA VIRUS

 #24
20230086531
2023-03-23

METHODS OF MANUFACTURING ACTIVATED IMMUNE CELLS

 #25
20230057304
2023-02-23

Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

 #26
20230022205
2023-01-26

CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY

 #27
20230008089
2023-01-12

Immuno-Oncolytic Therapies

 #28
20230008052
2023-01-12

CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF

 #29
20220389085
2022-12-08

TUMOR-TARGETING PROTEIN OR FRAGMENT THEREOF, ANTIBODY BINDING THERETO AND USE THEREOF

 #30
20220370527
2022-11-24

DELIVERY OF SIALIDASE TO CANCER CELLS, IMMUNE CELLS AND THE TUMOR MICROENVIRONMENT

 #31
20220362317
2022-11-17

IRF MODULATOR-EXPRESSING ONCOLYTIC VIRUSES FOR TREATING CANCER

 #32
20220362316
2022-11-17

PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS

 #33
20220339221
2022-10-27

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

 #34
20220339220
2022-10-27

THERAPEUTIC AGENTS COMPRISING ONCOLYTIC VACCINIA VIRUSES AND NK CELLS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS

 #35
20220290179
2022-09-15

GENETICALLY ENGINEERED ONCOLYTIC VACCINIA VIRUSES AND METHODS OF USES THEREOF

 #36
20220288143
2022-09-15

PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS

 #37
20220275370
2022-09-01

Striatin interacting protein inhibitor and use thereof in preparation of anti-tumor drug

 #38
20220275347
2022-09-01

ONCOLYTIC VACCINIA VIRUS

 #39
20220228128
2022-07-21

USE OF POXVIRUS WITH AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS FOR VACCINATION AND DISEASE THERAPY

 #40
20220211785
2022-07-07

USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS

 #41
20220133825
2022-05-05

ONCOLYTIC VIRUSES TARGETING STAT3

 #42
20220133824
2022-05-05

ONCOLYTIC VIRUSES TARGETING STAT3

 #43
20220064672
2022-03-03

ENGINEERED ONCOLYTIC VIRUSES EXPRESSING PD-L1 INHIBITORS AND USES THEREOF

 #44
20220056481
2022-02-24

M2-DEFECTIVE POXVIRUS

 #45
20220056480
2022-02-24

MODIFIED ORTHOPOXVIRUS VECTORS

 #46
20220049228
2022-02-17

Modified Extracellular Enveloped Virus

 #47
20210388388
2021-12-16

MUTANT VACCINIA VIRUSES AND USE THEREOF

 #48
20210338754
2021-11-04

HIGH MOBILITY GROUP BOX I MUTANT

 #49
20210322578
2021-10-21

ONCOLYTIC VACCINIA VIRUS CANCER THERAPY

 #50
20210315951
2021-10-14

Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy

 #51
20210230560
2021-07-29

SYNTHETIC CHIMERIC VACCINIA VIRUS

 #52
20210138053
2021-05-13

ANTI-TUMORAL COMPOSITION

 #53
20210009965
2021-01-14

Engineered vaccinia virus

 #54
20200392535
2020-12-17

Modified orthopoxvirus vectors

 #55
20200376052
2020-12-03

COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS

 #56
20200376051
2020-12-03

Immuno-modulated replication-efficient vaccinia virus strain

 #57
20200361998
2020-11-19

Compositions and methods for modulating inflammatory responses

 #58
20200338149
2020-10-29

NOVEL GENETICALLY ENGINEERED VACCINIA VIRUSES

 #59
20200318073
2020-10-08

Cell-based vehicles for potentiation of viral therapy

 #60
20200316198
2020-10-08

Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

 #61
20200289592
2020-09-17

Genetically engineered vaccinia viruses

 #62
20200289591
2020-09-17

Isolated Recombinant Oncolytic Poxvirus, Pharmaceutical Composition, and Use Thereof in Treatment of Tumors and/or Cancer

 #63
20200263145
2020-08-20

Recombinant vaccinia virus and methods of use thereof

 #64
20200237902
2020-07-30

Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

 #65
20200237839
2020-07-30

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy

 #66
20200222479
2020-07-16

Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors

 #67
20200216818
2020-07-09

VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY

 #68
20200197457
2020-06-25

Oncolytic virus for expression of immune checkpoint modulators

 #69
20200085891
2020-03-19

ONCOLYTIC VACCINIA VIRUS AND CHECKPOINT INHIBITOR COMBINATION THERAPY

 #70
20200010811
2020-01-09

Non-genetic modification of enveloped viruses

 #71
20200009269
2020-01-09

ONCOLYTIC VACCINIA VIRUS CANCER THERAPY

 #72
20190367886
2019-12-05

METHOD FOR PRODUCING VACCINIA VIRUS EXPRESSING FOREIGN GENE

 #73
20190367880
2019-12-05

Cell-based vehicles for potentiation of viral therapy

 #74
20190336552
2019-11-07

GENETICALLY ENGINEERED VACCINIA VIRUSES

 #75
20190336549
2019-11-07

Therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers

 #76
20190330655
2019-10-31

ONCOLYTIC VIRUSES AND THERAPEUTIC MOLECULES

 #77
20190307821
2019-10-10

METHODS AND COMPOSITIONS FOR CANCER THERAPY

 #78
20190218522
2019-07-18

Chimeric poxvirus compositions and uses thereof

 #79
20190209629
2019-07-11

High mobility group box I mutant

 #80
20190209622
2019-07-11

Schwann cell differentiation promoting agent and a peripheral nerve regeneration promoting agent

 #81
20190183947
2019-06-20

Oncolytic vaccinia virus mutants and using same for cancer treatment

 #82
20190175894
2019-06-13

Test method

 #83
20190169578
2019-06-06

Methods and compositions for production of vaccina virus

 #84
20190142883
2019-05-16

Oncolytic viruses targeting STAT3

 #85
20190054131
2019-02-21

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

 #86
20190046640
2019-02-14

Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

 #87
20190000899
2019-01-03

Anti-cancer oncolytic virus combination therapies and elite responder selection platforms

 #88
20180318366
2018-11-08

Method of treatment using oncolytic viruses

 #89
20180303886
2018-10-25

Compositions and methods for viral embolization

 #90
20180296653
2018-10-18

ANTI-TUMORAL COMPOSITION

 #91
20180271921
2018-09-27

Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof

 #92
20180256751
2018-09-13

ONCOLYTIC VACCINIA VIRUS CANCER THERAPY

 #93
20180236062
2018-08-23

Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

 #94
20180214538
2018-08-02

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

 #95
20180208904
2018-07-26

Host regulatory factor that enhances replication and/or propagation of vaccinia virus

 #96
20180195050
2018-07-12

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #97
20180078591
2018-03-22

Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors

 #98
20170340687
2017-11-30

Genetically engineered vaccinia viruses

 #99
20170298324
2017-10-19

Methods and compositions for production of vaccinia virus

 #100
20170173092
2017-06-22

Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof

 #101
20170157188
2017-06-08

Oncolytic virus for expression of immune checkpoint modulators

 #102
20170143780
2017-05-25

Combination of oncolytic virus with immune checkpoint modulators

 #103
20170095552
2017-04-06

Microorganisms for therapy

 #104
20170020938
2017-01-26

Oncolytic Vaccinia Virus

 #105
20160339066
2016-11-24

Oncolytic virus adjunct therapy with agents that increase virus infectivity

 #106
20160281066
2016-09-29

Mitogen-activated protein kinase-dependent recombinant vaccinia virus (MD-RVV) and use thereof

 #107
20160235793
2016-08-18

Immuno-oncolytic therapies

 #108
20160130564
2016-05-12

VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY

 #109
20160129135
2016-05-12

Oncolytic vaccinia virus cancer therapy

 #110
20160038548
2016-02-11

Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses

 #111
20160010064
2016-01-14

Mutant vaccinia virus strains, uses thereof and method of producing the same

 #112
20160000842
2016-01-07

ONCOLYTIC VIRUS

 #113
20150320800
2015-11-12

Immune effector cells pre-infected with oncolytic virus

 #114
20150250837
2015-09-10

ONCOLYTIC VIRUS ENCODING PD-1 BINDING AGENTS AND USES OF THE SAME

 #115
20150202325
2015-07-23

Oncolytic vaccinia virus cancer therapy

 #116
20150175976
2015-06-25

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #117
20150037355
2015-02-05

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

 #118
20150017126
2015-01-15

Poxviral oncolytic vectors

 #119
20140322173
2014-10-30

Oncolytic vaccinia virus combination cancer therapy

 #120
20140294891
2014-10-02

Microorganisms for therapy

 #121
20140234257
2014-08-21

Oncolytic viruses and methods for treating neoplastic disorders

 #122
20140162342
2014-06-12

Methods and compositions for production of vaccinia virus

 #123
20130287737
2013-10-31

Poxviral oncolytic vectors

 #124
20130230553
2013-09-05

Modulation of immune responses by the poxviral K4 protein

 #125
20130183271
2013-07-18

Methods and compositions concerning poxviruses and cancer

 #126
20130129614
2013-05-23

Microorganisms for imaging and/or treatment of tumors

 #127
20130039891
2013-02-14

POXVIRAL ONCOLYTIC VECTORS

 #128
20130028875
2013-01-31

Immune effector cells pre-infected with oncolytic virus

 #129
20120308484
2012-12-06

Clonal strains of attenuated vaccinia viruses and methods of use thereof

 #130
20120276053
2012-11-01

Oncolytic vaccinia virus cancer therapy

 #131
20120276010
2012-11-01

Microorganisms for therapy

 #132
20120244068
2012-09-27

Microorganisms for imaging and/or treatment of tumors

 #133
20120230958
2012-09-13

Oncolytic vaccinia virus combination cancer therapy

 #134
20120156168
2012-06-21

Viruses for the treatment of cellular proliferative disorders

 #135
20120114612
2012-05-10

Oncolytic viruses and methods for treating neoplastic disorders

 #136
20120052003
2012-03-01

MICROORGANISMS FOR PREVENTING AND TREATING NEOPLASMS ACCOMPANYING CELLULAR THERAPY

 #137
20110300176
2011-12-08

Microorganisms for therapy

 #138
20110293527
2011-12-01

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #139
20110206640
2011-08-25

Engineered synergistic oncolytic viral symbiosis

 #140
20110111051
2011-05-12

Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent

 #141
20110064650
2011-03-17

MICROORGANISMS FOR PREVENTING AND TREATING NEOPLASMS ACCOMPANYING CELLULAR THERAPY

 #142
20110059049
2011-03-10

Poxviral oncolytic vectors

 #143
20110044952
2011-02-24

AMPLIFICATION OF CANCER-SPECIFIC ONCOLYTIC VIRAL INFECTION BY HISTONE DEACETYLASE INHIBITORS

 #144
20110044948
2011-02-24

Poxviral oncolytic vectors

 #145
20100303714
2010-12-02

ONCOLYTIC VACCINIA VIRUS CANCER THERAPY

 #146
20100233078
2010-09-16

Microorganisms for imaging and/or treatment of tumors

 #147
20100203147
2010-08-12

Viruses for the treatment of cellular proliferative disorders

 #148
20100196325
2010-08-05

Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods

 #149
20100062016
2010-03-11

Microorganisms for therapy

 #150
20100021431
2010-01-28

Agent for promoting the production of thioredoxin

 #151
20100008946
2010-01-14

Microorganisms for therapy

 #152
20090162288
2009-06-25

Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods

 #153
20090155287
2009-06-18

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #154
20090136917
2009-05-28

Systems and methods for viral therapy

 #155
20090123382
2009-05-14

Light emitting microorganisms and cells for diagnosis and therapy of tumors

 #156
20090117049
2009-05-07

Light emitting microorganisms and cells for diagnosis and therapy of tumors

 #157
20090117048
2009-05-07

Light emitting microorganisms and cells for diagnosis and therapy of tumors

 #158
20090117047
2009-05-07

Light emitting microorganisms and cells for diagnosis and therapy of tumors

 #159
20090117034
2009-05-07

Microorganisms for imaging and/or treatment of tumors

 #160
20090098529
2009-04-16

Methods for attenuating virus strains for diagnostic and therapeutic uses

 #161
20090053244
2009-02-26

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #162
20090004723
2009-01-01

Methods and compositions concerning poxviruses and cancer

 #163
20080286237
2008-11-20

Systemic Treatment of Metastatic and/or Systemically-Disseminated Cancers using GM-CSF-Expressing Poxviruses

 #164
20080031886
2008-02-07

Viruses for the treatment of cellular proliferative disorders

 #165
20080019981
2008-01-24

Viruses for the treatment of cellular proliferative disorders

 #166
20080019980
2008-01-24

Viruses for the treatment of cellular proliferative disorders

 #167
20070212727
2007-09-13

Microorganisms for therapy

 #168
20070202572
2007-08-30

Microorganisms for therapy

 #169
20070154458
2007-07-05

Vaccinia virus expression vector for selective replication in a tumor cell and introduction of exogenous nucleotide sequence into a tumor cell

 #170
20070086984
2007-04-19

Viruses for the treatment of cellular proliferative disorders

 #171
20070077231
2007-04-05

Immune effector cells pre-infected with oncolytic virus

 #172
20070065411
2007-03-22

Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses

 #173
20070036758
2007-02-15

Mutants of vaccinia virus as oncolytic agents

 #174
20070025981
2007-02-01

Microorganisms for therapy

 #175
20060292113
2006-12-28

PROPHYLACTIC AND THERAPEUTIC TREATMENT OF THE DUCTAL EPITHELIUM OF A MAMMARY GLAND FOR CANCER

 #176
20060099224
2006-05-11

Methods and compositions concerning poxviruses and cancer

 #177
20060051370
2006-03-09

Microorganisms for therapy

 #178
20050281780
2005-12-22

Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer

 #179
20050069491
2005-03-31

Vaccinia virus for diagnosis and therapy of tumors

 #180
20050031643
2005-02-10

Microorganisms for therapy